Oral MS drug, Gilenya, Slowed Brain Loss in Study
Posted: Thu Mar 21, 2013 2:47 am
Novartis AG said its Gilenya drug to treat multiple sclerosis helped slow brain loss, a measure linked to the severity of the disease.
Patients taking Gilenya in three large Novartis-led studies lost a third less brain volume than patients taking either a placebo or Biogen Idec Inc. Avonex, Novartis said in an e- mailed statement today..... Read More - http://www.ms-uk.org/index.cfm/gilenya
Patients taking Gilenya in three large Novartis-led studies lost a third less brain volume than patients taking either a placebo or Biogen Idec Inc. Avonex, Novartis said in an e- mailed statement today..... Read More - http://www.ms-uk.org/index.cfm/gilenya